Upadacitinib for treating moderately to severely active ulcerative colitis

  • Technology appraisal guidance
  • TA856
  • Published: 

Resource impact statement

No significant resource impact is anticipated

NICE has recommended upadacitinib, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:

  • when conventional or biological treatment cannot be tolerated, or
  • if the condition has not responded well enough or has stopped responding to these treatments, and
  • if the company provides upadacitinib according to the commercial arrangement (see section 2 of guidance).

Choose the most appropriate treatment after discussing the advantages and disadvantages of the treatments available with the person having treatment. If patients and clinicians consider upadacitinib to be one of a range of suitable options, choose the least expensive treatment (taking into account drug administration costs, dose needed and frequency, and product price per dose).

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option and the overall cost of treatment for this patient group will be similar.

The previously published template for this patient group has been updated and replaced to include upadacitinib and all other treatment options for moderately to severely active ulcerative colitis.

Organisations should complete both current and future uptake based on local practice in order to assess the financial impact.

The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount. The other treatment options have discounts that are commercial in confidence. For enquiries about Patient Access Scheme (PAS) discounts contact the company, alternatively there may be confidential discounts at local or national levels arranged through networks.

This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.

ISBN: 978-1-4731-4931-1

This page was last updated: